Pharmaceutical CDMO Market Share To Reach Scalable Heights Of Growth

 Pharmaceutical CDMO Industry

The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.

In addition, increasing pharmaceutical R&D investments can drive the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in R&D activities of pharmaceuticals. For instance, in 2022, F. Hoffmann La Roche increased its R&D spending to USD 14.7 billion from USD 13.3 billion in the previous year. Another major player in pharmaceutical R&D expenditures for the same period was Merck & Co., allocating USD 13.5 billion to R&D. Janssen, the pharmaceutical arm of Johnson & Johnson, followed with an investment of USD 11.6 billion, slightly lower than the previous year's USD 11.9 billion.

Besides, increasing outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the market. The trend of outsourcing activities in pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, in the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across product development phases. At the same time, outsourcing serves as a risk-averse alternative. In addition, having a limited understanding of the required scale for current & future product offerings or market penetration poses significant hurdles in designing and scaling manufacturing for in-house production. Consequently, the preference for outsourcing has grown as an effective strategy until market demand for products becomes well-established & understood.

Gather more insights about the market drivers, restrains and growth of the Global Pharmaceutical CDMO market

Pharmaceutical CDMO Market Segments Highlights:

  • Based on product, the active pharmaceutical ingredient (API) segment led the market with the largest revenue share of 81.20% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and increasing geriatric population are some of the key factors propelling segment growth
  • Based on the workflow, the commercial segment held the largest market share in 2023 attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective
  • Based on application, the oncology segment dominated the market with the largest revenue share of 21.82% in 2023. The segment is driven by an increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology market

Pharmaceutical CDMO Market Report Segmentation

Grand View Research has segmented the pharmaceutical CDMO market report based on product, workflow, application, end-use, and region:

Pharmaceutical CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

  • API
    • Type
    • Synthesis
    • Drug
    • Manufacturing
  • Drug Product
    • Oral solid dose
    • Semi-solid dose
    • Liquid dose
    • Others

Pharmaceutical CDMO Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinical
  • Commercial

Pharmaceutical CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Hormonal Disorders
  • Hematological Disorders
  • Others

Pharmaceutical CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Small Pharmaceutical Companies
  • Medium Pharmaceutical Companies
  • Large Pharmaceutical Companies

Pharmaceutical CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Key Pharmaceutical CDMO Company Insights

  • Lonza
  • Thermo Fisher Scientific, Inc.
  • Recipharm AB
  • Laboratory Corporation of America Holdings (LabCorp)
  • Catalent, Inc.
  • WuXi AppTec, Inc.
  • Samsung Biologics
  • Piramal Pharma Solutions
  • Siegfried Holding AG
  • CordenPharma International
  • Cambrex Corporation
  • Bushu Pharmaceuticals Ltd.
  • Nipro Corporation

Order a free sample PDF of the Pharmaceutical CDMO Market Intelligence Study, published by Grand View Research.

 

Comments

Post a Comment

Popular posts from this blog

Food and Beverage ERP Solutions Procurement Intelligence: Food and Beverage ERP Solutions category is expected to have pricing growth outlook of 8.2% From 2023 To 2030

  Food and Beverage ERP Solutions Category Overview The food and beverage ERP solutions category is expected to grow at a CAGR of 8.2% from 2023 to 2030.Consumers are increasingly seeking transparency and traceability in the food and beverage business, which is fuelling this category's growth. ERP solutions can help businesses to track the origin of their ingredients and products, which can in turn help ensure food safety and meet consumer demand. The supply chain for the food and beverage industry is complex and has a wide range of players. ERP solutions can help businesses to optimize their supply chains, improve efficiency, and reduce costs. Technologies such as cloud computing, barcode scanning, and RFID labels are used under this category. Cloud computing offers a cost-effective and scalable solution for hosting ERP software, enabling remote access to data and applications. Barcode scanning is a fast and efficient method for tracking inventory and materials, improving traceabi...
Read more

Contact Center Software Market Worth $149.58 Billion By 2030

Contact Center Software Industry Overview The global contact center software market size was valued at USD 23.94 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 23.2% from 2022 to 2030.  The growth of the market can be attributed to the growing adoption of cloud-based and virtual contact center solutions to achieve better business continuity. Contact centers across the globe are focusing on transforming customer experience from a single interaction to an entire journey of consistent and personalized interactions. At this juncture, contact center software is helping businesses in ensuring a seamless customer experience across all communication channels. The strong emphasis businesses are putting on streamlining and personalizing customer interactions to enhance customer satisfaction is driving the growth of the market. According to a study by Salesforce.com, Inc., around 84% of customers consider the experience provided by a particular company e...
Read more

Manned Guarding Services Procurement Intelligence : Manned Guarding Services Category Is Expected to Grow at CAGR of 13.5% From 2024 to 2030

  Manned Guarding Services Category Overview The manned guarding services category is anticipated to witness growth at a CAGR of 13.5% from 2024 to 2030. Asia Pacific dominates the global category, followed by North America (with the fastest growth rate) and Europe. Rising standards of living, urbanization, and population are the key factors driving Asia Pacific’s growth. In addition, the region’s expanding tourism industry, coupled with political and economic stability, is also propelling the category’s expansion. The growing usage of technologies, such as access control systems and CCTV, is propelling the demand for the services offered in the category in North America. It has also helped companies to cut expenses while improving the safety of their employees and facilities. The demand in Europe is driven by the demand for more security at public events and venues and the growing incidence of terrorist incidents. Order your copy of the  Manned Guarding Services Pro...
Read more